Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.52 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.52 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.52 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.52 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679848 | 0.88 | SMN1; SMN2 (0.55) | ESR2CYP1A2CYP2A6CYP3A4CYP1A1 | |
| SCHEMBL14149752 | 0.87 | BACE1 (0.56) | ESR2BACE1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10068337 | 0.84 | ACHE (0.54) | CYP1A2CYP2D6CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL11242972 | 0.84 | BACE1 (0.51) | CYP1A2CYP2A6CYP3A4CYP1A1CYP2E1 | |
| SCHEMBL29402037 | 0.83 | PTPN1 (0.57) | CYP1A2CYP2A6CYP3A4CYP1A1CYP2E1 | |
| SCHEMBL12325013 | 0.83 | PTPN1 (0.57) | CYP1A2CYP2A6CYP3A4CYP1A1CYP2E1 | |
| SCHEMBL5551697 | 0.83 | PTPN1 (0.57) | CYP1A2CYP2A6CYP3A4CYP1A1CYP2E1 | |
| SCHEMBL19257213 | 0.83 | ACHE (0.57) | CYP1A2CYP2A6CYP3A4CYP1A1CYP2E1 | |
| SCHEMBL12326180 | 0.83 | CA1 (0.50) | CYP1A2CYP2A6CYP3A4CYP1A1CYP2E1 | |
| SCHEMBL16398888 | 0.82 | GSTP1 (0.53) | ESR2PPARGPPARAALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017479-B | Method for producing aromatic compound | 东曹株式会社 | 2022-07-29 | — | — | CN | disclosed |
| US-11311523-B2 | Pyridinone compound and use thereof | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| WO-2014057435-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MERCK PATNET GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| CN-1179791-C | Phosphinidene amide and transition metal complex catalyst and its synthesis process and application in C-C and C-N bond forming reaction | 中国科学院上海有机化学研究所 | 2004-12-15 | — | — | CN | disclosed |
| CN-1416954-A | Phosphinidene amide and transition metal complex catalyst and its synthesis process and application in C-C and C-N bond forming reaction | SHANGHAI INST ORGANIC CHEM (CN) | 2003-05-14 | — | — | CN | disclosed |
| EP-1144381-A2 | SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GmbH (DE) | 2001-10-17 | — | — | EP | disclosed |
| EP-1133475-A1 | SUBSTITUTED BENZO DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GmbH (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032577-A2 | SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GMBH (DE) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000031039-A1 | SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GMBH (DE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0324344-A1 | Fluoran derivatives | BASF Aktiengesellschaft (DE) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | ESR2 439/4885CYP1A2 184/4885CYP2A6 220/4885 |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MTTP, CETP, APOB | ESR2 1877/4885CYP1A2 279/4885CYP2A6 799/4885 |
| US-11311523-B2 | Pyridinone compound and use thereof | DOCK5, DOCK2, CIB1 | ESR2 4129/4885CYP1A2 2070/4885CYP2A6 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.